LONDON, ONTARIO--(Marketwire - June 13, 2008) - Critical Outcome Technologies Inc. (TSX VENTURE: COT), announced today that the Company has received confirmatory experimental results that have identified a novel and potentially first in class mechanism of action (MOA) for its lead cancer drug candidate, COTI-2. Experiments conducted in triplicate have confirmed that COTI-2 has a profound effect on caspase-9 activation through inhibition of Akt/PKB. The resulting activation of caspase 9 leads to a vigorous apoptosis or programmed cell death in cancer cells.
